Avenir Management Company’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Avenir Management Company’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$236K	Sell	45,650 -9,795	-18%	-$70.6K	0.54%	4
2023 Q2	$473K	Sell	55,445 -1	-0%	-$10	1.27%	4
2023 Q1	$654K	Hold	55,446	–	–	3.23%	4
2022 Q4	$798K	Hold	55,446	–	–	1.85%	6
2022 Q3	$2.78M	Hold	55,446	–	–	4.72%	6
2022 Q2	$4.72M	Hold	55,446	–	–	8.08%	4
2022 Q1	$8.37M	Hold	55,446	–	–	7.65%	2
2021 Q4	$16.6M	Buy	+55,446	New	+$21.3M	8.89%	2

Other funds holding FNCH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Avenir Management Company's FNCH Position: Q3 2023 in Review

Avenir Management Company reduced its Finch Therapeutics Group, Inc. Common Stock (FNCH) stake by 18% in Q3 2023, selling an estimated $70.6K and leaving 45,650 shares worth $236K. The position accounts for 0.54% of the portfolio, ranked #4.

Avenir Management Company first reported a position in FNCH in Q4 2021 and has held it in 8 quarters since. The position peaked at $16.6M in Q4 2021. 18 funds tracked by Wall St. Rank hold FNCH as of Q3 2023.

Avenir Management Company held 45,650 shares of Finch Therapeutics Group, Inc. Common Stock worth $236K as of Q3 2023.
Avenir Management Company sold 9,795 Finch Therapeutics Group, Inc. Common Stock shares in Q3 2023, an estimated $70.6K.
Finch Therapeutics Group, Inc. Common Stock made up 0.54% of Avenir Management Company's portfolio in Q3 2023, its #4 holding.
Avenir Management Company first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q4 2021 and has held it in 8 quarters since.
Avenir Management Company's Finch Therapeutics Group, Inc. Common Stock position peaked at $16.6M in Q4 2021.
18 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q3 2023.

Based on Avenir Management Company's 13F filing for Q3 2023, filed 14 Nov 2023.